Trials / Unknown
UnknownNCT05127135
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
A Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD7 in Patients With Refractory or Relapsed T Cell Malignancies
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Fundamenta Therapeutics, Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single dose escalation study to evaluate the safety and clinical activity of ThisCART7(Allogeneic CAR-T targeting CD7) in patients with refractory or relapsed CD7 positive T cell malignancies.
Detailed description
This is a single-center, nonrandomized, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART7 in patients with refractory or relapsed CD7 positive T cell malignancies, such as T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma and T-cell Non-Hodgkin Lymphoma. The dose range is 0.5-6 x 10\^6 cells per kg body weight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ThisCART7 cells | 0.5-6 x 10\^6 CAR T cells per kg body weight |
Timeline
- Start date
- 2020-01-22
- Primary completion
- 2023-01-24
- Completion
- 2023-12-24
- First posted
- 2021-11-19
- Last updated
- 2021-11-19
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05127135. Inclusion in this directory is not an endorsement.